Safe Harbour Statement

2/10/00


Click here to start


Table of Contents

PPT Slide

Safe Harbour Statement

SkyePharma - Company Overview

SkyePharma’s Mission

Increased Need for Drug Delivery

Main Sectors of Drug Delivery

SkyePharma’s Strategy

SkyePharma’s Technologies

Major Clients

2000 Key Value Drivers

DepoCyt™ - Near-term revenue driver

Xatral® 10mg OD

Solarase™

DepoMorphine™

Paxil™ CR

Requip™

Foradil - Novartis

Chiral Beta Agonist - Sepracor

PPT Slide

PPT Slide

New Product Partnerships

Business Development 97-99

PPT Slide

PPT Slide

DepoFoam™ - Injectable Delivery Technology

DepoFoam Versatility

SkyePharma’s Dry Powder Inhaler

SkyePharma DPI - 12 Month Storage

SkyePharma Non CFC MDI

SkyeFine™ Formulation Technology

GEOMATRIX® - Competitive Advantage

Geomatrix® - Formulation Flexibility

Enhancement Solubility Technology

Saturation solubility of model drug A

Topical - HA

Financial Overview

PPT Slide

Author: BlueScreen Global 1.0